Natalizumab in Inclusion Body Myositis (IBM)

Inclusion Body Myositis

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis Sporadic Inclusion Body Myositis Natural History Study Cell Therapy for IBM by Muscle Injection of ADSVF: a Phase I Trial Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells Phase III Trial of Sirolimus in IBM A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM) Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Natural History in CCFDN and IBM Syndromes Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Establishing Muscle Impedance Parameters With Electrical Impedance Myography Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis Study of Pioglitazone in Sporadic Inclusion Body Myositis Lithium in Inclusion Body Myositis (IBM) Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Study of Arimoclomol in Inclusion Body Myositis (IBM) An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Blood-flow Restricted Exercise in Inclusion Body Myositis Arimoclomol in Sporadic Inclusion Body Myositis – Open Label Extension Trial Molecular Profile of the Evolution of Inclusion Body Myositis Natalizumab in Inclusion Body Myositis (IBM) Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Arimoclomol in Sporadic Inclusion Body Myositis